`Sent: Friday, August 04, 2017 1:00 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Love, Jane M. <JLove@gibsondunn.com>; Trenchard, Robert W. <RTrenchard@gibsondunn.com>;
`Rea, Teresa <TRea@crowell.com>; Yellin, Deborah <DYellin@crowell.com>; Lentz, Shannon
`<SLentz@crowell.com>; Parmelee, Steve <sparmelee@wsgr.com>; Rosato, Michael
`<mrosato@wsgr.com>; 'Mills, Jad' <jmills@wsgr.com>
`Subject: IPR2017‐00854 and IPR2017‐01550
`
`Re: IPR2017‐00854 and IPR2017‐01550
`
`To the Patent Trial and Appeal Board:
`
`
`We represent Patent Owner Novartis in these IPRs. We write to inform the Board that Novartis
`does not object to Argentum’s Motion for Joinder of IPR2017‐01550 with now‐instituted
`IPR2017‐00854, as Argentum’s Petition in the 01550 IPR is substantively the same as the
`Petition in the 00854 IPR, and Argentum has agreed not to pursue any arguments or make any
`filings separate from those made by the Petitioner in the 00854 IPR. We accordingly
`respectfully request that the Board grant Argentum’s joinder motion, and Novartis hereby
`agrees not to submit any Preliminary Response to Argentum’s Petition. Novartis instead will
`proceed with a Patent Owner Response to the Petitions in both IPRs simultaneously.
`
`
`Respectfully submitted,
`Jane Love (Lead Counsel) and Robert Trenchard (Backup Counsel)
`
`
`Jane M. Love, Ph.D.
`
`GIBSON DUNN
`
`Gibson, Dunn & Crutcher LLP
`200 Park Avenue, New York, NY 10166-0193
`Tel +1 212.351.3922 • Fax +1 212.351.6322
`JLove@gibsondunn.com • www.gibsondunn.com
`
`
`
`